Many start-ups are emerging in developing countries, as governments are providing funds for the domestic development of synthetic biology. Siolta Therapeutics produces therapeutic microbial consortia to prevent and treat inflammatory illnesses. It evaluates clinical data and develops mixed-species therapies for oral supplementation. Unlike existing medications for allergies, the microbiome-based approach operates before the onset of the immune dysfunction cascade. STMC-103H, a flagship therapeutic candidate of Siolta Therapeutics, is being studied for the treatment of allergic asthma as well as other chronic inflammatory illnesses, including atopic dermatitis and allergic rhinitis. Similarly, Kinnva Ltd., established in 2017, is a synthetic biology start-up catering to biotech, cleantech, and Agri-tech segments. Using a unique fermentation technology and sophisticated processing methods, Kinnva produces high value biochemicals for applications in the food, feed, nutraceuticals, and cosmetics industries. Thus, start-ups are contributing significantly to the synthetic biology market expansion across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely
to drive the Europe synthetic biology market. The Europe synthetic biology market is expected to grow at a significant CAGR during the forecast period.
Europe Synthetic Biology Market Segmentation
The Europe synthetic biology market is analyzed based on products, technology, application, and country. Based on products, the market is segmented into enzymes, chassis organisms, oligonucleotides, and xeno-nucleic acids. The oligonucleotides segment dominated the market in 2020 and is expected to continue to grow at the fastest rate during the forecast period. Based on technology, the market is segmented into measurement & modeling, cloning & sequencing, genome engineering, gene synthesis, nanotechnology, and others. The gene synthesis segment dominated the market in 2020, while the genome engineering segment is expected to grow at the fastest CAGR during the forecast period. Based on application, the market is segmented into medical applications, industrial applications, food and agriculture, environmental applications, and others. The medical applications segment dominated the market in 2020 and is expected to grow at the highest CAGR during the forecast period. The Europe synthetic biology market is segmented into the UK, Germany, France, Italy, Spain, and Rest of Europe.
Agilent Technologies, Inc.; Amyris; Codexis; Genscript Biotech corporation; Integrated DNA Technologies; Merck KGaA; New England Biolabs; Novozymes A/S; Thermo Fisher Scientific; and Twist Bioscience are among the leading companies in the Europe synthetic biology market.